Clinical Trials Search at Vanderbilt-Ingram Cancer Center
A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (KEYMAKER-U03): Substudy 03C in Participants With Recurrent Disease During or After Anti-PD-(L)1 Adjuvant Therapy
Kidney (Renal Cell)
Kidney (Renal Cell)
Kidney (Renal Cell)
I/II
Rini, Brian
NCT07049926
VICCURO25011
Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)
Not Available
III
Not Available
NCT06401330
COGAREN2231
Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
Breast
Breast
This phase II trial tests how well evaluating circulating tumor deoxyribonucleic acid (ctDNA) works to guide therapy-change decisions in treating patients with triple-negative breast cancer (TNBC) that has spread from where it first started (primary site) to other places in the body (metastatic). This study wants to learn if small pieces of DNA associated with a tumor (called circulating tumor DNA, or ctDNA) can be detected in investigational blood tests during the course of standard chemotherapy treatment for breast cancer, and whether information from such investigational ctDNA blood testing could possibly be used as an early indication of chemotherapy treatment failure. It is hoped that additional information from investigational blood testing for ctDNA could help doctors to switch more quickly from a standard chemotherapy treatment that typically has significant side effects and which may not be working, to a different standard treatment regimen against TNBC, called sacituzumab govitecan. Sacituzumab govitecan is a monoclonal antibody, called hRS7, linked to a chemotherapy drug, called irinotecan. hRS7 is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as TROP2 receptors, and delivers irinotecan to kill them. Studying ctDNA may assist doctors to change therapy earlier if needed, and may improve health outcomes in patients with metastatic TNBC.
Breast
II
Abramson, Vandana
NCT05770531
VICCBRE2257
Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release
Multiple Myeloma
Multiple Myeloma
Multiple Myeloma
N/A
Oluwole, Olalekan
NCT04771078
VICCCTT24502
MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma - MASTER-2 Trial
Multiple Myeloma
Multiple Myeloma
Multiple Myeloma
II
Baljevic, Muhamed
NCT05231629
VICC-ITPCL23014
IMPACT: A Clinical Investigation on Improving Peripheral Neuropathy Induced by Chemotherapy with Advanced Compression Technology - A Safety and Efficacy Study
Miscellaneous
Miscellaneous
Miscellaneous
III
Agarwal, Rajiv
NCT07142304
VICCSUPP25037
